Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 20…
Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC Text with EEA relevance
In forceTyperegulationDate16 Apr 2014Since28 May 2014Articles99Versions held120Cited by135 documentsLast changed5 Dec 2022
- 4Prior authorisation
- 5Submission of an application
- 6Assessment report — Aspects covered by Part I
- 7Assessment report — Aspects covered by Part II
- 8Decision on the clinical trial
- 9Persons assessing the application
- 10Specific considerations for vulnerable populations
- 11Submission and assessment of applications limited to aspects covered by Part I or Part II of the assessment
- 12Withdrawal
- 13Resubmission
- 14Subsequent addition of a Member State concerned
- 15General principles
- 16Submission of application
- 17Validation of an application for the authorisation of a substantial modification of an aspect covered by Pa
- 18Assessment of a substantial modification of an aspect covered by Part I of the assessment report
- 19Decision on the substantial modification of an aspect covered by Part I of the assessment report
- 20Validation, assessment and decision regarding a substantial modification of an aspect covered by Part II of
- 21Substantial modification of aspects covered by Parts I and II of the assessment report
- 22Assessment of a substantial modification of aspects covered by Parts I and II of the assessment report — As
- 23Decision on the substantial modification of aspects covered by Parts I and II of the assessment report
- 24Persons assessing the application for a substantial modification
- 36Notification of the start of a clinical trial and of the end of the recruitment of subjects
- 37End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the res
- 38Temporary halt or early termination by the sponsor for reasons of subject safety
- 39Update of the contents of the summary of results and summary for laypersons
- 40Electronic database for safety reporting
- 41Reporting of adverse events and serious adverse events by the investigator to the sponsor
- 42Reporting of suspected unexpected serious adverse reactions by the sponsor to the Agency
- 43Annual reporting by the sponsor to the Agency
- 44Assessment by Member States
- 45Technical aspects
- 46Reporting with regard to auxiliary medicinal products
- 47Compliance with the protocol and good clinical practice
- 48Monitoring
- 49Suitability of individuals involved in conducting the clinical trial
- 50Suitability of clinical trial sites
- 51Traceability, storage, return and destruction of investigational medicinal products
- 52Reporting of serious breaches
- 53Other reporting obligations relevant for subject safety
- 54Urgent safety measures
- 55Investigator's brochure
- 56Recording, processing, handling and storage of information
- 57Clinical trial master file
- 58Archiving of the clinical trial master file
- 59Auxiliary medicinal products
- ANNEX I APPLICATION DOSSIER FOR THE INITIAL APPLICATION
- ANNEX II APPLICATION DOSSIER FOR SUBSTANTIAL MODIFICATION
- ANNEX III SAFETY REPORTING
- ANNEX IV CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL
- ANNEX V CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL FOR LAYPERSONS
- ANNEX VI LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS AND AUXILIARY MEDICINAL PRODUCTS
- ANNEX VII CORRELATION TABLE
Source: EU legislation in force, consolidated versions and treaties (Cellar, Publications Office). Official publication. Reuse: Reuse authorised (Commission Decision 2011/833/EU).